Biond Biologics lands $8M strategic investment from GIBF and launches China-based oncology joint venture
What's the deal? Israel-based Biond Biologics, a clinical-stage biotech developing cancer immunotherapies, has closed an $8M strategic investment from the Guangzhou-Israel Biotechnology Fund (GIBF). The two parties are also forming a China-based joint venture to advance Biond's oncology pipeline in the Chinese market.
The joint venture will focus on two lead programmes. BND-22 is a Phase 2 anti-ILT2 checkpoint inhibitor currently being evaluated at MD Anderson Cancer Center in cancers that rarely respond to existing immunotherapies. BND-67 is a first-in-class therapy targeting CD28 shedding — a novel immune evasion mechanism — with a Phase 1 trial planned for Q2 2026.
GIBF will contribute regulatory expertise, clinical development know-how, and local connections across China's biotech ecosystem.
Why now? Biond's pipeline is at an inflection point. BND-22 is already in Phase 2, and BND-67 is IND-ready. Securing a partner with deep roots in China lets the company pursue clinical trials and commercialisation in one of the world's fastest-growing oncology markets without building that infrastructure from scratch.
"The Chinese biotech market has rapidly evolved into a leading source of innovation, supported by high-quality clinical development and strong translational science," said Avner Lushi, managing partner of GIBF.
GIBF and Biond also said they are seeking additional collaborations across Asia to expand the company's geographic footprint.
What could go wrong? Cross-border biotech partnerships between Israel and China face geopolitical headwinds as Western governments scrutinise technology transfers to Chinese entities. Regulatory timelines in China can also be unpredictable, and the joint venture will need to navigate a competitive domestic oncology landscape crowded with local players.
Early-stage clinical programmes carry inherent risk — neither BND-22 nor BND-67 has yet demonstrated the kind of late-stage efficacy data that would de-risk the investment.
The signal: Dealroom classifies Biond Biologics as a "breakout" stage company, underscoring that it has moved beyond early R&D but still needs strategic capital to reach commercialisation — exactly the gap a joint-venture model with a regionally embedded fund like GIBF is designed to fill. The structure is notable: rather than a straightforward licensing deal, Biond is sharing equity upside and development risk with its China partner, a format that could become more common as clinical-stage biotechs seek capital-efficient routes into Asia's oncology market without diluting their global rights.
Read more: finanznachrichten.de
